enGene
Business Services · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4868 Rue Levy Ste 220, St. Laurent, Queb...Phone Number
(514) 332-4888Website
www.engene.comRevenue
$44.8 MillionStock Symbol
ENGNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
2
1
1
About enGene
enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral gene therapies to treat diseases with high unmet medical need. Its proprietary platform enables targeted delivery of DNA and RNA therapies, with a lead program focused on bladder cancer currently in late-stage clinical trials.Explore more
enGene Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is enGene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if enGene is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at enGene
enGene, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if enGene had a recent Job posting/layoffs
Product Launch: Get notified when enGene launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once enGene has new funding data
Earning: See what the market has to say on enGene recently announced quarterly report
Check if enGene has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to enGene
Compare insights from companies similar to enGene, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
enGene is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
enGene is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about enGene.
enGene financials insights
Gather financial insights about enGene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$13.3M
2015
Series B
$11.5M
2024
Share Placement
$60M
enGene Tech Stack
A closer look at the technologies used by enGene
Most Recent Scoops
Person-Based
Medical Research, Healthcare Operations
Open Position
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Branding, Acquisitions, Mergers
Person-Based
Person-Based
Product Development, Pharmaceuticals
enGene News & Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. (“Engene” or the “Company”) (NASDAQ: ENGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder ...
EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is among drug candidates for nonmuscle invasive bladder cancer (NMIBC)—and how questions over clinical data are enough to send investors scurrying to sell their shares.enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC May 7, 2026 8:00 AM EDTCompany...enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGene’s executive officers and whether investor losses may be recovered under federal securities laws.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding enGene
Sign Up For FreeTo access detailed company insights
enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral gene therapies to treat diseases with high unmet medical need. Its proprietary platform enables targeted delivery of DNA and RNA therapies, with a lead program focused on bladder cancer currently in late-stage clinical trials.... Read More
